LOUISVILLE, Ky., June 11, 2025 (GLOBE NEWSWIRE) — Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today announced that Ja Hillebrand, Chairman and CEO, Phil Poindexter, President and T. Clay Stinnett, EVP and CFO, will participate in the Stephens Investor Conference to be held June 16th and 17th in Portland, Maine, and will participate in a series of one-on-one meetings with institutional investors. Management’s discussion materials to be used at this conference will be posted to the investor section of the Company’s website, www.syb.com, on or before June 16, 2025. Louisville, Kentucky-based Stock Yards Bancorp, Inc., with $9.00 billion...

Adjustment of expectations RIAS A/SAttachment2025 06 Justering RIAS AS_UK vers.

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) — EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YTK), (“EnviroGold,” or the “Company”), a clean technology company focused on reprocessing mine waste to recover precious, base, and critical metals, is pleased to announce the appointment of Hatch Pty Ltd. (“Hatch”), a leading global professional services company, to deliver a high-level process review and engineering study in support of the commercialisation of EnviroGold’s proprietary NVRO Process™. The study will be conducted in relation to a confidential client project. The Hatch engineering study is expected to be completed in the fourth quarter of 2025. EnviroGold currently has two clients advancing through phases three and four of its Rapid Deployment Pathway, which culminate in client specific demonstration plant...

Dr. James Lee of the Francis Crick Institute will help guide development of PAS-004 for ETS2-driven diseases such as inflammatory bowel disease (IBD) MIAMI, June 11, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis and ankylosing spondylitis. Dr. Lee is the lead author on a 2024 Nature publication that identified ETS2 as a central regulator of macrophage-driven inflammation in IBD and other...